<SEC-DOCUMENT>0001209191-15-040240.txt : 20150507
<SEC-HEADER>0001209191-15-040240.hdr.sgml : 20150507
<ACCEPTANCE-DATETIME>20150507200536
ACCESSION NUMBER:		0001209191-15-040240
CONFORMED SUBMISSION TYPE:	3
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20150504
FILED AS OF DATE:		20150507
DATE AS OF CHANGE:		20150507

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Viking Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001607678
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				461073877
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		11119 NORTH TORREY PINES ROAD, SUITE 50
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92037
		BUSINESS PHONE:		858-550-7810

	MAIL ADDRESS:	
		STREET 1:		11119 NORTH TORREY PINES ROAD, SUITE 50
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92037

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			LIGAND PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0000886163
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		3
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37355
		FILM NUMBER:		15843679

	BUSINESS ADDRESS:	
		STREET 1:		11119 NORTH TORREY PINES ROAD
		STREET 2:		SUITE 200
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037
		BUSINESS PHONE:		858-550-7500

	MAIL ADDRESS:	
		STREET 1:		11119 NORTH TORREY PINES ROAD
		STREET 2:		SUITE 200
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037
</SEC-HEADER>
<DOCUMENT>
<TYPE>3
<SEQUENCE>1
<FILENAME>doc3.xml
<DESCRIPTION>FORM 3 SUBMISSION
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0206</schemaVersion>

    <documentType>3</documentType>

    <periodOfReport>2015-05-04</periodOfReport>

    <noSecuritiesOwned>0</noSecuritiesOwned>

    <issuer>
        <issuerCik>0001607678</issuerCik>
        <issuerName>Viking Therapeutics, Inc.</issuerName>
        <issuerTradingSymbol>VKTX</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0000886163</rptOwnerCik>
            <rptOwnerName>LIGAND PHARMACEUTICALS INC</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>11119 NORTH TORREY PINES ROAD, SUITE 200</rptOwnerStreet1>
            <rptOwnerStreet2></rptOwnerStreet2>
            <rptOwnerCity>LA JOLLA</rptOwnerCity>
            <rptOwnerState>CA</rptOwnerState>
            <rptOwnerZipCode>92037</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>1</isTenPercentOwner>
            <isOther>0</isOther>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable>
        <nonDerivativeHolding>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>4552859</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                    <footnoteId id="F1"/>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeHolding>
    </nonDerivativeTable>

    <derivativeTable>
        <derivativeHolding>
            <securityTitle>
                <value>Convertible Note (convertible into common stock)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>8.00</value>
            </conversionOrExercisePrice>
            <exerciseDate>
                <value>2016-05-04</value>
            </exerciseDate>
            <expirationDate>
                <footnoteId id="F2"/>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityValue>
                    <value>2500000.00</value>
                    <footnoteId id="F3"/>
                </underlyingSecurityValue>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeHolding>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">827,414 shares are held by Metabasis Therapeutics, Inc. (&quot;Metabasis&quot;), a wholly-owned subsidiary of Ligand Pharmaceuticals Incorporated (&quot;Ligand&quot;).</footnote>
        <footnote id="F2">The maturity date of the Convertible Note is May 21, 2016, subject to extension by Ligand in certain circumstances.</footnote>
        <footnote id="F3">Represents the aggregate principal amount outstanding under the Convertible Note. The Convertible Note is convertible into the number of shares of Common Stock equal to 200% of the principal amount plus accrued and previously unpaid interest thereon at the rate of 5% per annum. As of May 4, 2015, the Convertible Note would convert into 650,425 shares of Common Stock, which represents an aggregate value of $5,203,403 at the conversion price.</footnote>
    </footnotes>

    <remarks></remarks>

    <ownerSignature>
        <signatureName>/s/ Charles Berkman, Vice President and Secretary</signatureName>
        <signatureDate>2015-05-07</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
